This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sam Chun Dang Pharm. Co., Ltd.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Na-Won Park: Innovator in Ophthalmic Pharmaceutical Composition
Introduction
Na-Won Park is a distinguished inventor based in Suwon-si, South Korea. He has made significant contributions to the field of ophthalmic pharmaceuticals, particularly with his innovative formulations that enhance the efficacy and stability of treatments.
Latest Patents
Na-Won Park holds 1 patent for an ophthalmic pharmaceutical composition that includes aflibercept as an active ingredient. This composition is notable for its specific pH and the inclusion of an acetate salt buffering agent. It is designed to be free of ionic tonicity agents, which remarkably reduces the formation of dimeric and multimeric impurities. Furthermore, it maintains high biological activity over extended periods, even under accelerated stress conditions and cold storage.
Career Highlights
Na-Won Park is currently employed at Sam Chun Dang Pharm. Co., Ltd., where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing the field of ophthalmology, providing new options for patients in need of effective treatments.
Collaborations
Na-Won Park has collaborated with notable colleagues, including Guang-Jin Im and Byung-Jhip Ha, to further enhance the research and development of ophthalmic compositions.
Conclusion
Na-Won Park's contributions to ophthalmic pharmaceuticals exemplify the impact of innovation in healthcare. His work not only advances medical science but also improves patient outcomes through effective treatment options.